HRYZ Biotech
China - GuangzhouBiotechnology
Focus: HRYZ Biotech is a China-based cell therapy specialist focused on oncology, developing multiple autologous and allogeneic cellular therapies (MASCT platform) targeting solid tumors and hematologic malignancies. The company operates from Guangzhou with an early-stage pipeline primarily in Phase 1 development.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About HRYZ Biotech
AI assessmentNot HiringNo open roles listed right now. Follow HRYZ Biotech to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
MASCT-I
Advanced Gastric CancerClinical Trials (1)
NCT03393416A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor
Phase 1Help build intelligence for HRYZ Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.